Targeted drug may prolong survival of patients with cervical cancer

(Wiley) A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news